In approximately 10% of soft-tissue sarcomas, largely irrespective of histological subtype and possibly independent of JUN amplification status, JNK inhibitors that can replace the inhibitory function no longer provided by SERPINB3 may restore JNK activity to normal condition. The gene discussed is JUN; the disease is soft tissue sarcoma.